AbbVieEyetoEye的动态

???Excited to share our latest prototype of the OcuTap, an ophthalmic syringe designed for anterior chamber paracentesis! This innovative device features single-hand operation for enhanced physician control and an integrated collection tube to minimize sample contamination and maximize volume for analysis. Stay tuned for more updates!??????#MedicalInnovation #Ophthalmology #HealthcareTech #Prototype

If you have something to say about #medicaldevices #sterilization and #endotoxin, this is a great time to get involved! Endotoxin of terminally sterilized devices has been getting a lot more attention since the updated FDA guidance on premarket submissions for sterile devices added "implants" to the list of products in scope for endotoxin limit criteria. There is some explanation in past versions of ST72 for the historical exclusion of orthopedic devices from endotoxin testing. There are a few current and upcoming projects for updating endotoxin standards: - AAMI/ST72:2019 is under review by AAMI ST/WG08 to look at updating the standard for better alignment with ISO 11737-3 and (possibly) to include some information on recombinant endotoxin testing as an alternative to LAL and (hopefully) to update some of the language related to sterilization effect on endotoxin based on some recent papers - ISO 11737-3 - published in 2023, this should come up for review next in 2028. Updates to the international standard are a bit harder to predict that far out and with more people involved but there is a good possibility that some of the updates going through now in ST72 will be reflected in future versions of the international standard. - USP <86> new general chapter "Bacterial endotoxin test using recombinant reagents". The latest news release I've seen on this has the expert committee voting around the last week of June with possible publication between November 2024 and May 2025 if approved.

Surgical Sutures Market Revenue to Hit $4.9 Billion by 2026 ???????????????? ?????? ????????????????: https://lnkd.in/gGtF2NX3 The global surgical sutures market in terms of revenue was estimated to be worth $3.7 billion in 2021 and is poised to reach $4.9 billion by 2026, growing at a CAGR of 6.0% from 2021 to 2026. Related Reports - Wound Dressings Market: https://lnkd.in/duGEBC_4 Advanced Wound Care Market: https://lnkd.in/dUffh949 Ethicon, Inc. Medtronic BKK B. Braun Melsungen AG AG Advanced Medical Solutions Internacional Farmaceutica, S.A. de C.V. Peters Surgical SURGICAL SPECIALTIES, PSC. Boston Scientific DemeTECH Corporation Healthium Medtech Limited Zimmer Biomet Stryker Smith & Nephew Group Plc CONMED Corporation Mellon Medical BV ENDOEVOLUTION MICROVAL Anchora Medical Ltd. Lotus Surgicals And Lab Needs Universal Sutures

Did you know implants can be sterilely used directly after unpacking? The packaging and sterilization service helps hospitals simplify their processes and reduce the risk of infection after surgery. Früh takes responsibility for a germ-free implant. Would you like to know more about it? https://ow.ly/Mso150R6pft #Protect2Perform #packagingsolutions #sterilization

#Morpheus8 #Secures First and Only #FDA #Clearance for #Soft #Tissue #Contraction for Fractional #Radiofrequency #Microneedling InMode is pleased to announce an additional FDA clearance for #Morpheus8. #Morpheus8 is the first and only fractional radiofrequency (FRF) microneedling technology cleared for contraction of soft tissue. The (FDA) has cleared the use of the #Morpheus8 Applicators for the delivery of #fractional #radiofrequency use in dermatologic skin procedures where #coagulation/ #contraction of soft tissue or #hemostasis is needed. "#InMode is #dedicated to investing in R&D so we can provide medical professionals with #continued #advancements they need to #deliver the #highest #quality of care and best-in-class #results," said?Moshe Mizrahy, #CEO of InMode. "The new indication for soft tissue contraction enhances the product's intended use, helping Morpheus8 practitioners expand their patient base." Since inception, #Morpheus8 has gained widespread global brand awareness, with more than 2.5 #million #procedures performed worldwide, and an average of 8.2 treatments performed every minute. Read the full press release here https://lnkd.in/gV6MG26U

Chloroprocaine ophthalmic gel 3% (IHEEZO) does not act as a barrier to the bactericidal actions of povidone-iodine 5% and that the reduction in CFU from PVI is similar when compared with tetracaine 0.5% ophthalmic solution with PVI.

#Facial_Aesthetics Market Estimated to Expand at a Robust CAGR over 2023–2032 https://lnkd.in/dGD_xFHJ The demand for facial #aesthetics treatment has increased significantly. The ability to provide #dramatic benefits without surgery has been a perfect element of attraction. Other factors like procedures that can be made without #anesthesia, downtime, and significant #discomfort have been an equal #contributor to rising growth. Allergan Merz Aesthetics Merz Aesthetics Latam Galderma VALEANT PHARMACEUTICALS INTERNATIONAL INC Mentor Worldwide LLC ANIKA THERAPEUTICS S.R.L. Adoderm TEOXANE Laboratories Teoxane UK Limited Vivariant Laboratories Prollenium Medical Technologies Inc. Speciality European Pharma Speciality European Pharma #facialaesthetics #aesthetics #dermalfillers #beauty #fillers #skincare #lipfiller #antiaging #lips #facialrejuvenation #botox #facialtreatment #lipfillers #facial #lipenhancement #injectables #antiwrinkle #dermalfiller #juvederm #beforeandafter #skin #lipaugmentation #nonsurgical #cheekfillers #aestheticmedicine #facialcare #facials #skincareroutine #medicalaesthetics #facialmassage

Regenerative medicine company Orthocell Ltd (ASX:OCC, OTC:ORHHF) has chalked up record revenue of A$2.03 million for the September 2024 quarter, marking a second consecutive quarter of record growth. The figures are a 7.82% increase on the A$1.88 million achieved in the June quarter, driven by growing demand for its market-leading flagship assets, Striate+? and Remplir?. Striate+, used for dental bone regeneration, is currently sold in key global markets, including the US, Canada, Europe, the UK, Australia and New Zealand. Remplir, a product designed for peripheral nerve repair, is available in Australia and New Zealand, with further international expansion planned. As a result of their strong clinical performance, both products are seeing increasing uptake among surgeons. Orthocell is targeting new regulatory approvals to expand into additional markets. More at #Proactive #ProactiveInvestors #ASX #OCC #Biotech #Medtech #RegenerativeMedicine https://ow.ly/n9i4105L9e7

Market Scope estimates that nearly 2,000 vitrectomy machines were sold globally in 2023. Looking forward, however, the percentage of United States retinal surgeons planning to purchase a new vitrectomy machine in the next 12 months continues to fall, down to only 2 percent in 2023 from a high of 6 percent in 2020. The main growth drivers for vitrectomy machines are typically technology upgrades, surgery center expansion, market penetration, and replacements. However, it’s possible a recent acquisition could prove to be a driver on its own. ZEISS Medical Technology’s December acquisition of DORC Dutch Ophthalmic Research Center (International) combines the strong reputation of the Eva vitrectomy machine with Zeiss’ status as a global market leader with extensive financial resources and established sales networks—all while filling the biggest void in Zeiss’ product line. Will this acquisition convince more surgeons it’s time to purchase a new machine? We will be closely monitoring this and much more in our Ophthalmic Market Trends—Quarterly US Retina Edition.??? ? These concise, unbiased expert-reviewed, survey-based editions are published every quarter to drive innovation and uncover competitive intelligence. Coverage includes vitrectomy volume and locations, vitrectomy machine use and market share, reusable and disposable instruments, visualization agents, IVT injections by disease and product, DME treatments, corticosteroid use, and photocoagulation volume and usage. Please visit https://bit.ly/Q223OMT4 to learn more about these trends and subscribe, or email [email protected] to request a sample. #Vitrectomy #Machine #RetinalSurgery #PurchasePlans #MarketDrivers #Ophthalmology #Ophthalmic